Significance
Alzheimer's disease (AD) patients develop amyloid deposits, containing amyloid-β (Aβ) fibrils, in their brain tissue. Although amyloid is a likely contributor to AD dementia, similar amyloid loads occur in some nondemented elderly individuals. Molecular structures of Aβ fibrils are known to be variable. We, therefore, investigate whether structures of Aβ fibrils derived from cerebral cortical tissue of nondemented elderly subjects differ from structures from AD patients. We find statistically significant, but subtle, differences between NMR spectra of Aβ fibrils from nondemented elderly subjects and analogous spectra of fibrils from AD patients. Thus, similar structures develop but with different relative populations on average. Other factors may be primary determinants of cognitive status in individuals with high amyloid loads.
Keywords: amyloid structure, Alzheimer’s disease, solid-state NMR
Abstract
Although amyloid plaques composed of fibrillar amyloid-β (Aβ) assemblies are a diagnostic hallmark of Alzheimer's disease (AD), quantities of amyloid similar to those in AD patients are observed in brain tissue of some nondemented elderly individuals. The relationship between amyloid deposition and neurodegeneration in AD has, therefore, been unclear. Here, we use solid-state NMR to investigate whether molecular structures of Aβ fibrils from brain tissue of nondemented elderly individuals with high amyloid loads differ from structures of Aβ fibrils from AD tissue. Two-dimensional solid-state NMR spectra of isotopically labeled Aβ fibrils, prepared by seeded growth from frontal lobe tissue extracts, are similar in the two cases but with statistically significant differences in intensity distributions of cross-peak signals. Differences in solid-state NMR data are greater for 42-residue amyloid-β (Aβ42) fibrils than for 40-residue amyloid-β (Aβ40) fibrils. These data suggest that similar sets of fibril polymorphs develop in nondemented elderly individuals and AD patients but with different relative populations on average.
Amyloid plaques in brain tissue, containing fibrils formed by amyloid-β (Aβ) peptides, are one of the diagnostic pathological signatures of Alzheimer's disease (AD). Clear genetic and biomarker evidence indicates that Aβ is key to AD pathogenesis (1). However, Aβ is present as a diverse population of multimeric assemblies, ranging from soluble oligomers to insoluble fibrils and plaques, and may lead to neurodegeneration by a number of possible mechanisms (2–7).
One argument against a direct neurotoxic role for Aβ plaques and fibrils in AD is the fact that plaques are not uncommon in the brains of nondemented elderly people, as shown both by traditional neuropathological studies (8, 9) and by positron emission tomography (10–13). On average, the quantity of amyloid is greater in AD patients (10) and (at least in some studies) increases with decreasing cognitive ability (12, 14, 15) or increasing rate of cognitive decline (16). However, a high amyloid load does not necessarily imply a high degree of neurodegeneration and cognitive impairment (11, 13, 17).
A possible counterargument comes from studies of the molecular structures of Aβ fibrils, which show that Aβ peptides form multiple distinct fibril structures, called fibril polymorphs (18–20). Polymorphism has been demonstrated for fibrils formed by both 40-residue amyloid-β (Aβ40) (19, 21–24) and 42-residue amyloid-β (Aβ42) (22, 25–29) peptides, the two main Aβ isoforms. Among people with similar total amyloid loads, variations in neurodegeneration and cognitive impairment may conceivably arise from variations in the relative populations of different fibril polymorphs. As a hypothetical example, if polymorph A was neurotoxic but polymorph B was not, then people whose Aβ peptides happened to form polymorph A would develop AD, while people whose Aβ peptides happened to form polymorph B would remain cognitively normal. In practice, brains may contain a population of different propagating and/or neurotoxic Aβ species, akin to prion quasispecies or “clouds,” and the relative proportions of these and their dynamic interplay may affect clinical phenotype and rates of progression (30).
Well-established connections between molecular structural polymorphism and variations in other neurodegenerative diseases lend credence to the hypothesis that Aβ fibril polymorphism plays a role in variations in the characteristics of AD. Distinct strains of prions causing the transmissible spongiform encephalopathies have been shown to involve different molecular structural states of the mammalian prion protein PrP (30–32). Distinct tauopathies involve different polymorphs of tau protein fibrils (33–37). In the case of synucleopathies, α-synuclein has been shown to be capable of forming polymorphic fibrils (38–40) with distinct biological effects (41–43).
Experimental support for connections between Aβ polymorphism and variations in characteristics of AD comes from polymorph-dependent fibril toxicities in neuronal cell cultures (19), differences in neuropathology induced in transgenic mice by injection of amyloid-containing extracts from different sources (44–46), differences in conformation and stability with respect to chemical denaturation of Aβ assemblies prepared from brain tissue of rapidly or slowly progressing AD patients (47), and differences in fluorescence emission spectra of structure-sensitive dyes bound to amyloid plaques in tissue from sporadic or familial AD patients (48, 49).
Solid-state NMR spectroscopy is a powerful method for investigating fibril polymorphism because even small, localized changes in molecular conformation or structural environment produce measurable changes in 13C and 15N NMR chemical shifts (i.e., in NMR frequencies of individual carbon and nitrogen sites). Full molecular structural models for amyloid fibrils can be developed from large sets of measurements on structurally homogeneous samples (21, 25, 26, 29, 38, 50). Alternatively, simple two-dimensional (2D) solid-state NMR spectra can serve as structural fingerprints, allowing assessments of polymorphism and comparisons between samples from different sources (22, 51).
Solid-state NMR requires isotopic labeling and milligram-scale quantities of fibrils, ruling out direct measurements on amyloid fibrils extracted from brain tissue. However, Aβ fibril structures from autopsied brain tissue can be amplified and isotopically labeled by seeded fibril growth, in which fibril fragments (i.e., seeds) in a brain tissue extract are added to a solution of isotopically labeled peptide (21, 22, 52). Labeled “daughter” fibrils that grow from the seeds retain the molecular structures of the “parent” fibrils, as demonstrated for Aβ (19, 21, 24, 53) and other (54, 55) amyloid fibrils. Solid-state NMR measurements on the brain-seeded fibrils then provide information about molecular structures of fibrils that were present in the brain tissue at the time of autopsy. Using this approach, Lu et al. (21) developed a full molecular structure for Aβ40 fibrils derived from one AD patient with an atypical clinical history (patient 1), showed that Aβ40 fibrils from a second patient with a typical AD history (patient 2) were qualitatively different in structure, and showed that the predominant brain-derived Aβ40 polymorph was the same in multiple regions of the cerebral cortex from each patient. Subsequently, Qiang et al. (22) prepared isotopically labeled Aβ40 and Aβ42 fibrils from frontal, occipital, and parietal lobe tissue of 15 patients in three categories, namely typical long-duration Alzheimer's disease (t-AD), the posterior cortical atrophy variant of Alzheimer's disease (PCA-AD), and rapidly progressing Alzheimer's disease (r-AD). Quantitative analyses of 2D solid-state NMR spectra led to the conclusions that Aβ40 fibrils derived from t-AD and PCA-AD tissue were indistinguishable, with both showing the same predominant polymorph; that Aβ40 fibrils derived from r-AD tissue were more structurally heterogeneous (i.e., more polymorphic); and that Aβ42 fibrils derived from all three categories were structurally heterogeneous, with at least two prevalent Aβ42 polymorphs (22).
In this paper, we address the question of whether Aβ fibrils that develop in cortical tissue of nondemented elderly individuals with high amyloid loads are structurally distinguishable from fibrils that develop in cortical tissue of AD patients. As described below, quantitative analyses of 2D solid-state NMR spectra of brain-seeded samples indicate statistically significant differences for both Aβ40 and Aβ42 fibrils. Differences in the 2D spectra are subtle, however, indicating that nondemented individuals and AD patients do not develop entirely different Aβ fibril structures. Instead, data and analyses described below suggest overlapping distributions of fibril polymorphs, with different relative populations on average.
Results
Preparation of Aβ Fibrils.
Aβ40 and Aβ42 fibrils were prepared by seeded growth using an amyloid-containing extract from human frontal lobe tissue as the source of seeds. As in the experiments of Qiang et al. (22), Aβ40 was 15N,13C labeled at F19, V24, G25, S26, A30, I31, L34, and M35, and Aβ42 was 15N,13C labeled at F19, G25, A30, I31, L34, and M35. Tissue samples were obtained from the Religious Orders Study of the Rush Alzheimer's Disease Center (RADC) (56). Eight samples were selected from subjects assessed as lacking cognitive impairment but with high cortical Aβ levels measured by immunohistochemistry (SI Appendix, SI Methods and Table S1). Ages at death ranged from 85 to 100 y.
Extracts were prepared as described previously (21, 22). Fibrils were then grown with the protocol depicted in Fig. 1A. This protocol is identical to the one used by Qiang et al. (22), except that isotopically labeled Aβ, solubilized in dimethyl sulfoxide (DMSO), was added to the sonicated suspension of tissue extract in two steps rather than in a single step (SI Appendix, SI Methods). This modification of the seeded growth protocol was necessary because tissue samples from RADC were only 0.5 to 0.6 g, whereas tissue samples in the experiments of Qiang et al. (22) were ∼2.0 to 3.0 g. By adding Aβ in two steps, the ratio of DMSO-solubilized Aβ to extract at the beginning of fibril growth was kept approximately constant. To minimize the likelihood of preferential amplification of specific polymorphs (57), sonication conditions that fragment all polymorphs were used, multiple rounds of seeded growth were avoided, and the ratio of Aβ in seeds to soluble Aβ in the second step was large (2:13 ratio).
Fibril samples derived from RADC tissue are denoted RADCnf, with n = 1, 2, … 8 and with “f” indicating frontal lobe tissue. Fig. 1 B and C shows examples of transmission electron microscope (TEM) images of Aβ40 and Aβ42 fibrils after the initial 4-h growth period and after the subsequent 18- to 24-h period. Full sets of TEM images are shown in SI Appendix, Figs. S1 and S2. The TEM images at 4 h show fibrils in all cases, whereas previously reported control experiments with extracts from human cortical tissue that was devoid of Aβ plaques resulted in no detectable fibrils after 4 h (21, 22). The morphologies of Aβ40 and Aβ42 fibrils in the TEM images could not be assessed reliably because, in many cases, extraneous material from the tissue extracts adhered to or partially obscured the fibrils. It should be noted that our tissue extracts are heterogeneous materials, with amyloid representing only a small fraction of the total mass.
Solid-State NMR Spectroscopy of Aβ40 Fibrils.
Fig. 2 A and B shows examples of 2D 13C-13C solid-state NMR spectra of Aβ40 fibrils prepared by seeded growth from RADC tissue extracts. The 2D spectrum in Fig. 2A exhibits a single set of relatively sharp and strong cross-peaks, with little intensity in additional signals. This spectrum, therefore, suggests a single predominant Aβ40 fibril polymorph in the RADC1f sample. Additional signals in Fig. 2B, indicated by cyan arrows, suggest the presence of at least one additional polymorph with a substantial population in the RADC4f sample. One-dimensional (1D) spectra of all eight RADC Aβ40 samples (SI Appendix, Fig. S3 A and C) show variations in the relative intensities and shapes of the 13C solid-state NMR lines, suggesting variations in polymorph populations. The full set of 2D 13C-13C spectra is shown in SI Appendix, Fig. S4.
For comparison, Fig. 2 C and D shows 2D 13C-13C solid-state NMR spectra of Aβ40 fibrils prepared by seeded growth from one of the t-AD tissue extracts examined by Qiang et al. (22) (sample t-AD4f) and Aβ40 fibrils prepared in vitro without seeding. Spectra in Fig. 2 B and C are similar to one another, whereas the spectrum in Fig. 2D shows broader cross-peaks and additional signals, indicating greater structural heterogeneity in the final fibril sample when fibril growth is initiated by spontaneous nucleation, rather than by seeding.
Fig. 2 E–H shows 2D 15N-13C solid-state NMR spectra of the same Aβ40 fibrils as in Fig. 2 A–D. Again, the spectrum of the RADC4f sample (Fig. 2F) shows additional cross-peak signals that are not detectable in the spectrum of the RADC1f sample (Fig. 2E). The spectrum of the t-AD4f sample (Fig. 2G) is similar to that of the RADC4f sample, but differences are more readily apparent than in the 2D 13C-13C spectra. The 2D 15N-13C spectrum of the unseeded sample (Fig. 2H) obviously contains many cross-peak signals that are not present in spectra of the other three samples. The 2D 15N-13C spectra of all eight RADC Aβ40 samples are shown in SI Appendix, Fig. S5.
Solid-State NMR Spectroscopy of Aβ42 Fibrils.
Fig. 3 shows 2D 13C-13C and 15N-13C solid-state NMR spectra of RADC3f and RADC7f Aβ42 fibrils, t-AD1f Aβ42 fibrils from the work of Qiang et al. (22), and unseeded Aβ42 fibrils. The 2D spectra of all eight RADC Aβ42 fibrils are shown in SI Appendix, Figs. S6 and S7. Both types of 2D spectra show clear differences between the RADC3f and RADC7f samples, suggesting that the main Aβ42 fibril polymorphs in these two samples are different. The 2D spectra of t-AD1f Aβ42 fibrils are also different from the two RADC samples. The 2D spectra of the unseeded Aβ42 fibrils contain broader cross-peaks and additional cross-peaks, indicating greater structural heterogeneity.
As with the Aβ40 fibrils, 1D spectra of all eight RADC Aβ42 samples (SI Appendix, Fig. S3 B and D) show variations in the relative intensities and shapes of the 13C solid-state NMR lines. These spectra also show large variations in total signal amplitude (e.g., a factor of four difference between RADC4f and RADC8f Aβ42 samples) (SI Appendix, Fig. S3D), although the amount of isotopically labeled Aβ42 used in the seeded fibril growth protocol was the same for each sample. Variations in signal amplitude are attributable to variations in the quantities of seed-competent Aβ42 amyloid in the tissue samples. In particular, signals from the RADC2f Aβ42 sample were very weak, leading to barely detectable cross-peaks in 2D spectra of this sample (SI Appendix, Figs. S6 and S7).
rmsd Analyses.
If the brain-seeded Aβ40 and Aβ42 fibril samples contained only a small number of polymorphs and if their cross-peak signals were well resolved in the 2D spectra, then it would be possible to estimate the populations of individual polymorphs in each sample from cross-peak volumes in the 2D spectra. In reality, however, the 2D spectra contain complicated cross-peak patterns, with contributions from multiple polymorphs that are not well resolved. Therefore, we used two objective methods for quantitatively analyzing and comparing 2D spectra that do not require assignment of cross-peaks to individual polymorphs (58).
In the first method, we calculated pairwise root-mean-squared deviations (rmsds) among signal amplitudes in the 2D spectra after identifying regions of the spectra that contain signals above the noise level, normalizing the total signal amplitudes, and optimizing the relative scaling of signal amplitudes (SI Appendix, SI Methods). Fig. 4 displays pairwise rmsds among 2D solid-state NMR spectra of Aβ40 and Aβ42 fibrils as heat maps, with small rmsd values in blue, intermediate values in white and yellow, and large values in red. The 2D spectra of the eight RADC-seeded samples are included (59), along with 2D spectra of t-AD and PCA-AD samples reported previously by Qiang et al. (22, 60). [The 2D spectra of all t-AD and PCA-AD samples appear in extended data figures 2 and 3 of the paper by Qiang et al. (22) and are available at https://data.mendeley.com/datasets/tbp45pm92x/1.] Fibrils derived by seeded growth from amyloid-containing extracts of t-AD and PCA-AD tissue samples are denoted by t-ADnx and PCAnx, where n is the patient number and x is “f,” “o,” or “p” for frontal, occipital, or parietal lobe tissue, respectively. Although rmsd values vary considerably when spectra within or between each of the three tissue categories (i.e., RADC, t-AD, and PCA-AD) are compared, the overall color patterns in Fig. 4 suggest that 2D spectra of RADC samples are more similar to one another (i.e., have smaller pairwise rmsds on average) than to 2D spectra of t-AD or PCA-AD samples. Moreover, as shown previously by Qiang et al. (22), t-AD and PCA-AD samples appear to be indistinguishable. The sensitivity of rmsd values to differences among 2D spectra is evident, for example, from the observation that 2D 13C-13C spectra of RADC1f and t-AD4f fibrils appear similar in the contour plots in Fig. 2 but have rmsd = 0.28, while 2D 13C-13C spectra of RADC6f and RADC7f are more nearly identical in SI Appendix, Fig. S4 and have rmsd = 0.08.
Three statistical tests were used to evaluate the significance of the apparent differences in rmsd values. Results are summarized in Table 1. The 2D spectra of RADC2f Aβ42 were not included in these tests, due to their low signal-to-noise ratios.
Table 1.
Data type | Comparison 1 | rmsd 1 | Comparison 2 | rmsd 2 | KS D statistic | KS critical value | WMW U statistic | WMW P value | WTT ν | WTT t statistic | WTT P value |
2D 13C-13C Aβ40 | RADC vs. RADC (n = 56) | 0.246 (0.104) | RADC vs. t-AD (n = 176) | 0.311 (0.065) | 0.312* | 0.222* | 3,224.5* | <0.001* | 69.10* | –4.322* | <0.001* |
2D 13C-13C Aβ40 | RADC vs. RADC (n = 56) | 0.246 (0.104) | RADC vs. PCA-AD (n = 144) | 0.359 (0.104) | 0.456* | 0.228* | 1,811.5* | <0.001* | 90.19* | –7.032* | <0.001* |
2D 13C-13C Aβ40 | RADC vs. RADC (n = 56) | 0.246 (0.104) | RADC vs. t-AD + PCA-AD (n = 320) | 0.332 (0.082) | 0.357* | 0.210* | 5,036* | <0.001* | 67.34* | –5.827* | <0.001* |
2D 15N-13C Aβ40 | RADC vs. RADC (n = 56) | 0.263 (0.079) | RADC vs. t-AD (n = 176) | 0.354 (0.088) | 0.537* | 0.222* | 2,113* | <0.001* | 101.17* | –7.197* | <0.001* |
2D 15N-13C Aβ40 | RADC vs. RADC (n = 56) | 0.263 (0.079) | RADC vs. PCA-AD (n = 96) | 0.302 (0.079) | 0.359* | 0.243* | 1,748* | <0.001* | 90.08* | –3.133* | 0.002* |
2D 15N-13C Aβ40 | RADC vs. RADC (n = 56) | 0.263 (0.079) | RADC vs. t-AD + PCA-AD (n = 272) | 0.336 (0.083) | 0.473* | 0.213* | 3,861* | <0.001* | 81.24* | –6.112* | <0.001* |
2D 13C-13C Aβ42 | RADC vs. RADC (n = 42) | 0.378 (0.196) | RADC vs. t-AD (n = 98) | 0.549 (0.146) | 0.388* | 0.266* | 1,235.5* | <0.001* | 59.39* | –3.792* | <0.001* |
2D 13C-13C Aβ42 | RADC vs. RADC (n = 42) | 0.378 (0.196) | RADC vs. PCA-AD (n = 98) | 0.483 (0.123) | 0.218† | 0.266† | 1,731† | 0.137† | 58.63† | –1.50† | 0.139† |
2D 13C-13C Aβ42 | RADC vs. RADC (n = 42) | 0.378 (0.196) | RADC vs. t-AD + PCA-AD (n = 196) | 0.516 (0.147) | 0.260* | 0.246* | 2,966.5* | 0.004* | 50.67* | –2.761* | 0.008* |
2D 15N-13C Aβ42 | RADC vs. RADC (n = 42) | 0.339 (0.159) | RADC vs. t-AD (n = 98) | 0.487 (0.147) | 0.340* | 0.266* | 1,248.5* | <0.001* | 75.41* | –3.888* | <0.001* |
2D 15N-13C Aβ42 | RADC vs. RADC (n = 42) | 0.339 (0.159) | RADC vs. PCA-AD (n = 56) | 0.435 (0.126) | 0.202† | 0.294† | 981† | 0.162† | 84.79† | –1.558† | 0.122† |
2D 15N-13C Aβ42 | RADC vs. RADC (n = 42) | 0.339 (0.159) | RADC vs. t-AD + PCA-AD (n = 154) | 0.468 (0.146) | 0.260* | 0.252* | 2,229.5* | 0.002* | 63.65* | –3.262* | 0.002* |
KS tests used α = 0.05. WMW P values are two-tail values. The WTT degree of freedom is ν. rmsd 1 and rmsd 2 values are mean values, with SDs in parentheses. The KS and WMW tests evaluate whether distributions of rmsd values from comparisons 1 and 2 are significantly different. The WTT test evaluates whether the mean rmsd values are significantly different.
*Statistically significant differences between rmsd values for comparison 1 and rmsd values for comparison 2.
†An absence of statistical significance.
First, the two-sample Kolmogorov–Smirnov (KS) test was used to determine whether distributions of rmsd values for pairs of spectra of RADC samples were significantly different from distributions of rmsd values between spectra of RADC samples and spectra of t-AD samples, PCA-AD samples, and combined t-AD and PCA-AD samples. Significant differences (i.e., D statistic greater than critical value, with significance parameter α = 0.05) were found in nearly all cases for both Aβ40 and Aβ42 fibrils and for both 2D 13C-13C spectra and 2D 15N-13C spectra. The only exceptions were when rmsds between 2D spectra of pairs of RADC Aβ42 samples were compared with rmsds between spectra of RADC Aβ42 samples and spectra of PCA-AD Aβ42 samples. The absence of statistical significance in these cases may be due to the small number of PCA-AD Aβ42 samples for which 2D spectra were available.
Next, the two-tail, two-sample Wilcoxon–Mann–Whitney (WMW) test was used to confirm the KS results. The WMW test indicated significant differences between distributions of rmsd values (P ≤ 0.002) in all cases where differences were significant according to the KS test.
Finally, Welch's t test (WTT) was used to determine the statistical significance of differences between the average rmsd value for pairs of spectra of RADC samples and the average rmsd value between spectra of RADC samples and spectra of t-AD samples, PCA-AD samples, and combined t-AD and PCA-AD samples. Again, differences were found to be significant (P ≤ 0.002) in all cases except when rmsds between 2D spectra of pairs of RADC Aβ42 samples were compared with rmsds between spectra of RADC Aβ42 samples and spectra of PCA-AD Aβ42 samples.
In addition to the unseeded in vitro fibrils whose spectra are shown in Figs. 2 D and H and 3 D and H, Aβ40 and Aβ42 fibrils were grown in the presence of extract from occipital lobe tissue that was devoid of detectable amyloid (22). SI Appendix, Fig. S8 shows 2D spectra of these fibrils, along with their rmsds relative to the 2D spectra of RADC, t-AD, and PCA-AD fibril samples. In most cases, rmsd values in SI Appendix, Fig. S8 are greater than the values in Table 1. Thus, we have no evidence that nonamyloid components of cortical tissue extracts promote the formation of the specific fibril polymorphs that we observe in fibrils created by seeding with amyloid-containing extracts.
Principal Component Analyses.
As a second method of assessing similarities and differences among samples, we used principal component analysis (49, 61, 62). As applied to 2D solid-state NMR spectra (22), principal component analysis is a mathematical procedure for representing each experimental 2D spectrum as a linear combination of principal component spectra , with principal values ηq and coefficients ckq [i.e., , where N is the number of experimental 2D spectra and ν1 and ν2 are the two frequency axes of the 2D spectra]. Principal values are nonnegative, and principal component spectra are ordered by decreasing principal value (i.e., if q < q′). The first principal component is an approximate average of the experimental 2D spectra. Subsequent principal components represent variations among the experimental 2D spectra with decreasing importance.
Principal component analyses were carried out as described in SI Appendix, SI Methods, including spectra of RADC, t-AD, and PCA-AD samples. The total number of 2D spectra was n = 28 for 2D 13C-13C spectra of Aβ40 fibrils, n = 25 for 2D 15N-13C spectra of Aβ40 fibrils, n = 22 for 2D 13C-13C spectra of Aβ42 fibrils, and n = 19 for 2D 15N-13C spectra of Aβ42 fibrils. The first three principal component spectra for each set of 2D spectra are plotted in SI Appendix, Figs. S9 and S10. Principal values are plotted in SI Appendix, Fig. S11.
Values of the coefficients ck1, ck2, and ck3 from principal component analyses of the four sets of 2D spectra are plotted in Fig. 5. As expected, average values of ck1 are nearly equal for RADC, t-AD, and PCA-AD samples. Average values of ck2 and ck3 vary, suggesting differences among 2D spectra from the three tissue categories. As for the rmsd analyses, three statistical tests were used to evaluate significance. Results are summarized in Table 2.
Table 2.
Data type | Principal component | Tissue category | n | Average coefficient | KS D statistic | KS critical value | WMW U statistic | WMW P value | WTT ν | WTT t statistic | WTT P value |
2D 13C-13C Aβ40 | 1 | RADC | 8 | 0.192 (0.031) | |||||||
2D 13C-13C Aβ40 | 1 | t-AD | 11 | 0.182 (0.035) | 0.318† | 0.637† | 53† | 0.467† | 16.09† | 0.623† | 0.542† |
2D 13C-13C Aβ40 | 1 | PCA-AD | 9 | 0.184 (0.042) | 0.222† | 0.663† | 37† | 0.925† | 14.61† | 0.435† | 0.670† |
2D 13C-13C Aβ40 | 1 | t-AD + PCA-AD | 20 | 0.183 (0.037) | 0.200† | 0.579† | 90† | 0.618† | 15.29† | 0.630† | 0.538† |
2D 13C-13C Aβ40 | 2 | RADC | 8 | −0.225 (0.197) | |||||||
2D 13C-13C Aβ40 | 2 | t-AD | 11 | 0.061 (0.094) | 0.750* | 0.637* | 11* | 0.004* | 9.34* | –3.804* | 0.004* |
2D 13C-13C Aβ40 | 2 | PCA-AD | 9 | 0.131 (0.071) | 0.875* | 0.663* | 4* | 0.001* | 8.613* | –4.843* | 0.001* |
2D 13C-13C Aβ40 | 2 | t-AD + PCA-AD | 20 | 0.093 (0.090) | 0.750* | 0.579* | 15* | <0.001* | 8.193* | –4.383* | 0.002* |
2D 13C-13C Aβ40 | 3 | RADC | 8 | −0.086 (0.263) | |||||||
2D 13C-13C Aβ40 | 3 | t-AD | 11 | 0.036 (0.148) | 0.409† | 0.637† | 34† | 0.418† | 10.217† | –1.183† | 0.264† |
2D 13C-13C Aβ40 | 3 | PCA-AD | 9 | 0.082 (0.143) | 0.500† | 0.663† | 16† | 0.053† | 10.539† | –1.607† | 0.138† |
2D 13C-13C Aβ40 | 3 | t-AD + PCA-AD | 20 | 0.057 (0.144) | 0.45† | 0.579† | 50† | 0.129† | 8.732† | –1.450† | 0.182† |
2D 15N-13C Aβ40 | 1 | RADC | 8 | 0.197 (0.023) | |||||||
2D 15N-13C Aβ40 | 1 | t-AD | 11 | 0.198 (0.029) | 0.284† | 0.637† | 43† | 0.936† | 16.909† | –0.104† | 0.918† |
2D 15N-13C Aβ40 | 1 | PCA-AD | 6 | 0.199 (0.038) | 0.333† | 0.729† | 21† | 0.708† | 7.621† | –0.115† | 0.911† |
2D 15N-13C Aβ40 | 1 | t-AD + PCA-AD | 17 | 0.199 (0.031) | 0.199† | 0.592† | 64† | 0.820† | 18.784† | –0.137† | 0.893† |
2D 15N-13C Aβ40 | 2 | RADC | 8 | −0.134 (0.198) | |||||||
2D 15N-13C Aβ40 | 2 | t-AD | 11 | 0.093 (0.201) | 0.568† | 0.637† | 18* | 0.029* | 15.374* | –2.467* | 0.026* |
2D 15N-13C Aβ40 | 2 | PCA-AD | 6 | 0.070 (0.102) | 0.625† | 0.729† | 10† | 0.070† | 10.911* | –2.516* | 0.029* |
2D 15N-13C Aβ40 | 2 | t-AD + PCA-AD | 17 | 0.085 (0.169) | 0.574† | 0.592† | 28* | 0.017* | 12.013* | –2.712* | 0.019* |
2D 15N-13C Aβ40 | 3 | RADC | 8 | −0.092 (0.173) | |||||||
2D 15N-13C Aβ40 | 3 | t-AD | 11 | 0.030 (0.246) | 0.364† | 0.637† | 28† | 0.191† | 16.996† | –1.275† | 0.219† |
2D 15N-13C Aβ40 | 3 | PCA-AD | 6 | 0.028 (0.144) | 0.458† | 0.729† | 15† | 0.255† | 11.812† | –1.427† | 0.180† |
2D 15N-13C Aβ40 | 3 | t-AD + PCA-AD | 17 | 0.030 (0.210) | 0.390† | 0.592† | 43† | 0.148† | 16.617† | –1.531† | 0.144† |
2D 13C-13C Aβ42 | 1 | RADC | 8 | −0.233 (0.023) | |||||||
2D 13C-13C Aβ42 | 1 | t-AD | 7 | −0.193 (0.021) | 0.857* | 0.702* | 5* | 0.005* | 12.947* | –3.511* | 0.004* |
2D 13C-13C Aβ42 | 1 | PCA-AD | 7 | −0.204 (0.025) | 0.607† | 0.702† | 10* | 0.034* | 12.229* | –2.296* | 0.040* |
2D 13C-13C Aβ42 | 1 | t-AD + PCA-AD | 14 | −0.199 (0.023) | 0.714* | 0.610* | 15* | 0.003* | 14.881* | –3.374* | 0.004* |
2D 13C-13C Aβ42 | 2 | RADC | 8 | 0.186 (0.130) | |||||||
2D 13C-13C Aβ42 | 2 | t-AD | 7 | −0.197 (0.205) | 0.875* | 0.702* | 54* | 0.001* | 9.933* | 4.255* | 0.002* |
2D 13C-13C Aβ42 | 2 | PCA-AD | 7 | −0.044 (0.106) | 0.875* | 0.702* | 51* | 0.005* | 12.951* | 3.766* | 0.002* |
2D 13C-13C Aβ42 | 2 | t-AD + PCA-AD | 14 | −0.121 (0.176) | 0.875* | 0.610* | 105* | <0.001* | 18.408* | 4.661* | <0.001* |
2D 13C-13C Aβ42 | 3 | RADC | 8 | −0.075 (0.326) | |||||||
2D 13C-13C Aβ42 | 3 | t-AD | 7 | −0.007 (0.113) | 0.375† | 0.702† | 27† | 0.911† | 8.843† | –0.547† | 0.598† |
2D 13C-13C Aβ42 | 3 | PCA-AD | 7 | 0.107 (0.095) | 0.500† | 0.702† | 19† | 0.308† | 8.334† | –1.505† | 0.169† |
2D 13C-13C Aβ42 | 3 | t-AD + PCA-AD | 14 | −0.050 (0.116) | 0.375† | 0.610† | 46† | 0.504† | 8.033† | –1.043† | 0.328† |
2D 15N-13C Aβ42 | 1 | RADC | 8 | −0.220 (0.017) | |||||||
2D 15N-13C Aβ42 | 1 | t-AD | 7 | −0.241 (0.037) | 0.589† | 0.702† | 39† | 0.210† | 8.241† | 1.333† | 0.218† |
2D 15N-13C Aβ42 | 1 | PCA-AD | 4 | −0.220 (0.028) | 0.375† | 0.813† | 17† | 0.871† | 4.185† | –0.039† | 0.970† |
2D 15N-13C Aβ42 | 1 | t-AD + PCA-AD | 11 | −0.233 (0.034) | 0.420† | 0.637† | 56† | 0.330† | 15.512† | 1.063† | 0.304† |
2D 15N-13C Aβ42 | 2 | RADC | 8 | 0.197 (0.067) | |||||||
2D 15N-13C Aβ42 | 2 | t-AD | 7 | −0.185 (0.229) | 1.000* | 0.702* | 56* | <0.001* | 6.897* | 4.263* | 0.004* |
2D 15N-13C Aβ42 | 2 | PCA-AD | 4 | 0.030 (0.180) | 0.750† | 0.813† | 27† | 0.060† | 3.423† | 1.801† | 0.158† |
2D 15N-13C Aβ42 | 2 | t-AD + PCA-AD | 11 | −0.107 (0.230) | 0.909* | 0.637* | 83* | <0.001* | 12.225* | 4.151* | 0.001* |
2D 15N-13C Aβ42 | 3 | RADC | 8 | −0.070 (0.358) | |||||||
2D 15N-13C Aβ42 | 3 | t-AD | 7 | 0.047 (0.031) | 0.625† | 0.702† | 19† | 0.308† | 7.121† | –0.918† | 0.389† |
2D 15N-13C Aβ42 | 3 | PCA-AD | 4 | 0.100 (0.027) | 0.750† | 0.831† | 8† | 0.183† | 7.157† | –1.328† | 0.225† |
2D 15N-13C Aβ42 | 3 | t-AD + PCA-AD | 11 | 0.066 (0.039) | 0.625† | 0.637† | 27† | 0.164† | 7.119† | –1.068† | 0.321† |
Results from WMW, KS, and WTT tests in t-AD, PCA-AD, and t-AD + PCA-AD rows represent comparisons with principal component coefficients of RADC data.
*Statistically significant differences from coefficients for RADC samples.
†An absence of statistical significance.
The KS test indicates that the distribution of c2k values for 2D 13C-13C spectra of RADC Aβ40 fibrils differs significantly (α = 0.5) from distributions of c2k values for 2D 13C-13C spectra of t-AD Aβ40 fibrils, PCA-AD Aβ40 fibrils, and combined t-AD and PCA-AD Aβ40 fibrils. The same is true for 2D 13C-13C spectra of Aβ42 fibrils. The KS test also indicates significant differences between the distribution of c2k values for 2D 15N-13C spectra of RADC Aβ42 fibrils and distributions of c2k values for 2D 15N-13C spectra of t-AD Aβ42 fibrils and combined t-AD and PCA-AD Aβ42 fibrils, as well as significant differences between the distribution of c1k values for 2D 13C-13C spectra of RADC Aβ42 fibrils and distributions of c1k values for 2D 13C-13C spectra of t-AD Aβ42 fibrils and combined t-AD and PCA-AD Aβ42 fibrils.
The WMW test indicates significant differences (P ≤ 0.005) in all cases where differences were significant according to the KS test. Additionally, the WMW test indicates significant differences (P ≤ 0.029) between the distribution of c2k values for 2D 15N-13C spectra of RADC Aβ40 fibrils and distributions of c2k values for 2D 15N-13C spectra of t-AD Aβ40 fibrils and combined t-AD and PCA-AD Aβ42 fibrils, as well as a significant difference (P = 0.034) between the distribution of c1k values for 2D 13C-13C spectra of RADC Aβ42 fibrils and the distribution of c1k values for 2D 13C-13C spectra of PCA-AD Aβ42 fibrils.
Finally, for both Aβ40 and Aβ42 fibrils and for both 2D 13C-13C spectra and 2D 15N-13C spectra, WTT indicates significant differences (P ≤ 0.029) between average values of c2k for RADC samples and average values of c2k for t-AD samples, PCA-AD samples, and combined t-AD and PCA-AD samples, except when 2D 15N-13C spectra of RADC Aβ42 samples are compared with 2D 15N-13C spectra of PCA-AD Aβ42 samples. WTT also indicates significant differences (P ≤ 0.040) between the average value of c1k for 2D 13C-13C spectra of RADC Aβ42 fibrils and the average values of c1k for 2D 13C-13C spectra of t-AD Aβ42 fibrils, PCA-AD Aβ42 fibrils, and combined t-AD and PCA-AD Aβ42 fibrils.
Discussion
How Do Aβ Fibrils from Nondemented Subjects Differ from Aβ Fibrils from AD Patients?
As described above, we have prepared isotopically labeled Aβ40 and Aβ42 fibrils by seeded growth from amyloid-containing extracts of cortical tissue from nondemented subjects with high amyloid loads (RADC samples), carried out solid-state NMR measurements on these fibrils, and compared the resulting 2D solid-state NMR spectra with previously reported (22) 2D spectra of isotopically labeled Aβ40 and Aβ42 fibrils derived from cortical tissue of AD patients (t-AD and PCA-AD samples). Both rmsd and principal component analyses indicate statistically significant differences between spectra from RADC samples and spectra from t-AD and PCA-AD samples.
However, the differences are subtle. The 2D spectra are variable, both for fibrils derived from tissue of nondemented subjects (Figs. 2 and 3 and SI Appendix, Figs. S4–S7) and for fibrils derived from tissue of AD patients (22). For example, 2D spectra of RADC1f Aβ40 fibrils show a single set of strong cross-peak signals, indicating a single predominant structure and minimal polymorphism, while spectra of RADC3f Aβ40 fibrils show multiple sets of signals, indicating a greater degree of polymorphism. Roughly speaking, 2D spectra of other RADC Aβ40 fibrils are intermediate between those of RADC1f and RADC3f.
As a means of visualizing the differences between typical 2D spectra of fibrils derived from the three tissue categories, we constructed 2D spectra from the first three principal components (SI Appendix, Figs. S9 and S10) using the average values of c1k, c2k, and c3k for each category. The resulting “average 2D spectra” are shown in Figs. 6 and 7. For Aβ40 fibrils (Fig. 6), average 2D 13C-13C and 15N-13C spectra of RADC samples are similar to the corresponding average spectra of t-AD and PCA-AD spectra (which are essentially indistinguishable from one another). Differences in the relative intensities of cross-peak components arising from F19, V24, G25, and S26 are indicated by magenta arrows. For S26 and V24, the positions of maximal cross-peak intensity are shifted in the average 2D 13C-13C spectra of t-AD and PCA-AD samples, relative to the positions of maximal cross-peak intensity in the average 2D 13C-13C spectra of RADC samples.
For Aβ42 (Fig. 7), differences between average 2D spectra of RADC samples and average 2D spectra of t-AD and PCA-AD samples are more pronounced. The most obvious differences are in the relative intensities of cross-peak components arising from F19, G25, A30, and I31. For G25, A30, and I31, positions of maximal cross-peak intensity are shifted in average 2D 13C-13C or 15N-13C spectra of t-AD and PCA-AD samples, relative to corresponding positions of maximal cross-peak intensity in average 2D spectra of RADC samples.
Thus, from the average 2D spectra, it appears that both nondemented subjects and AD patients develop distributions of Aβ40 and Aβ42 polymorphs in their cortical tissue. The distributions for nondemented subjects and AD patients overlap but exhibit statistically significant differences. The most obvious differences in the average 2D spectra are in cross-peak signals arising from G25, A30, and I31 in brain-seeded Aβ42 fibrils. Other isotopically labeled residues in both Aβ40 and Aβ42 fibrils also exhibit significant differences in their average cross-peak intensity distributions.
Aβ40 vs. Aβ42.
Our finding of greater differences on average for Aβ42 fibrils suggests that the distribution of Aβ42 fibril polymorphs in cortical tissue may be more predictive of cognitive impairment than the distribution of Aβ40 fibril polymorphs. It should be recognized that cross-seeding between different Aβ isoforms, as observed in vitro under certain circumstances (63), may affect this finding. If cross-seeding is significant, solid-state NMR data for Aβ42 may not reflect only the properties of Aβ42 fibrils in the original tissue. Nonetheless, it seems unlikely that seeding of Aβ42 by Aβ40 fibrils in our tissue extracts would produce greater structural variations among brain-seeded Aβ42 fibrils than among brain-seeded Aβ40 fibrils. Moreover, even if the molecular structures and structural distributions of brain-seeded fibrils in our experiments do not precisely match those of fibrils in the original cortical tissue, the fact that we see differences in solid-state NMR spectra of fibrils derived from different groups of tissue samples supports the existence of structural differences in the original fibrils.
Implications for the Role of Aβ Fibril Polymorphism in AD.
Work described above was motivated by the goal of determining whether Aβ fibrils that develop in brain tissue of nondemented elderly subjects are structurally distinct from those that develop in brain tissue of AD patients. If clear differences in fibril structure exist, it would provide a potential explanation for the observation of high amyloid loads in some elderly individuals who are cognitively normal according to standard assessments (11, 13, 17). Our finding that 2D solid-state NMR spectra of fibrils derived from cortical tissue of nondemented elderly individuals exhibit statistically significant differences from, but are nonetheless similar to, spectra of fibrils derived from cortical tissue of AD patients is best explained by the occurrence of the same or similar sets of fibril polymorphs in both cases but with differences in the relative populations of these polymorphs on average. It is conceivable that certain polymorphs with enhanced populations in AD patients contribute most strongly to neurodegeneration. On the other hand, our data certainly do not rule out the possibility that factors other than Aβ fibril polymorphism are the primary determinants of cognitive status in subjects with high amyloid loads.
It has been proposed that cognitively normal subjects with high amyloid loads are in a preclinical phase of AD, meaning that they would eventually develop dementia (64). The absence of detectable cognitive impairment may be a consequence of large cognitive reserve in these individuals (65) and/or differential susceptibility to Aβ-induced neurotoxicity via variation in Aβ receptors (7). If neurodegeneration is driven largely by tau pathology that develops as a consequence of amyloid deposition (66), then variations in the strength of the Aβ-tau connection or susceptibility to tau-induced dysfunction could explain variations in cognitive impairment among individuals with high amyloid loads. The differences in relative populations of Aβ fibril polymorphs indicated by the solid-state NMR data could then conceivably be a consequence of feedback, in which a neurodegenerative state, originally induced by amyloid formation, later alters the rates of clearance and self-propagation of certain Aβ fibril polymorphs. In this scenario, development of AD in some individuals with high amyloid loads, but not in others, would not be determined by differences in their Aβ fibril structures. However, after neurodegeneration became more pronounced in some individuals, the relative populations of various polymorphs in brain tissue of those with or without obvious cognitive impairment could become different on average.
Methods
Brain tissue extracts were prepared as previously described (21, 22). Fibrils were grown as described above and depicted in Fig. 1A. Solid-state NMR spectra were obtained with standard pulse sequences using magnetic field strengths of 14.1 and 17.5 T and magic-angle spinning frequencies of 13.6 and 17.0 kHz, respectively; rmsd and principal component analyses of 2D spectra were performed as previously described (22). Full details of samples, experiments, and data analyses are given in SI Appendix, SI Methods.
Acknowledgments
This work was supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, NIH. The Medical Research Council (MRC) Prion Unit at University College London (UCL) is funded by the UK Medical Research Council and the National Institute of Health Research University College London Hospital/UCL Biomedical Research Centre. We thank Drs. David Bennett and Zoe Arvanitakis of RADC for providing tissue samples, with support from NIH Grants P30AG010161 and R01AG15819. We are grateful for the assistance of S. Mead, O. Avwenagha, and J. Wadsworth at the MRC Prion Unit in the selection and processing of AD tissue samples. We thank all patients and their families for consent to use tissues in research. We also thank the Queen Square Brain Bank for Neurological Disorders (supported by the Reta Lila Weston Trust for Medical Research, the Progressive Supranuclear Palsy [Europe] Association, and the MRC) at the UCL Institute of Neurology for provision of AD tissue samples.
Footnotes
The authors declare no competing interest.
This article is a PNAS Direct Submission.
This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2111863118/-/DCSupplemental.
Data and Code Availability.
The 2D solid-state NMR spectra data that support the findings of this study have been deposited in Mendeley Data (https://data.mendeley.com/datasets/dj34fwjhkt/1). Computer programs written specifically for the analyses in Figs. 4 and 5 have been deposited in Mendeley Data (https://data.mendeley.com/datasets/3zzc2dhx26/1). Previously published data were also used for this work (https://data.mendeley.com/datasets/tbp45pm92x/1).
References
- 1.Selkoe D. J., Hardy J., The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Deane R., Zlokovic B. V., Role of the blood-brain barrier in the pathogenesis of Alzheimer’s disease. Curr. Alzheimer Res. 4, 191–197 (2007). [DOI] [PubMed] [Google Scholar]
- 3.Eikelenboom P., et al., Neuroinflammation - An early event in both the history and pathogenesis of Alzheimer’s disease. Neurodegener. Dis. 7, 38–41 (2010). [DOI] [PubMed] [Google Scholar]
- 4.Jarosz-Griffiths H. H., Noble E., Rushworth J. V., Hooper N. M., Amyloid-β receptors: The good, the bad, and the prion protein. J. Biol. Chem. 291, 3174–3183 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Pithadia A. S., Lim M. H., Metal-associated amyloid-β species in Alzheimer’s disease. Curr. Opin. Chem. Biol. 16, 67–73 (2012). [DOI] [PubMed] [Google Scholar]
- 6.Delgado D. A., et al., Distinct membrane disruption pathways are induced by 40-residue β-amyloid peptides. J. Biol. Chem. 291, 12233–12244 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Purro S. A., Nicoll A. J., Collinge J., Prion protein as a toxic acceptor of amyloid-β oligomers. Biol. Psychiatry 83, 358–368 (2018). [DOI] [PubMed] [Google Scholar]
- 8.Giannakopoulos P., Hof P. R., Michel J. P., Guimon J., Bouras C., Cerebral cortex pathology in aging and Alzheimer’s disease: A quantitative survey of large hospital-based geriatric and psychiatric cohorts. Brain Res. Brain Res. Rev. 25, 217–245 (1997). [DOI] [PubMed] [Google Scholar]
- 9.Savva G. M., et al., Medical Research Council Cognitive Function and Ageing Study, Age, neuropathology, and dementia. N. Engl. J. Med. 360, 2302–2309 (2009). [DOI] [PubMed] [Google Scholar]
- 10.Aizenstein H. J., et al., Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65, 1509–1517 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Mathis C. A., et al., In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Ann. Neurol. 73, 751–761 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Grothe M. J., Ewers M., Krause B., Heinsen H., Teipel S. J.; Alzheimer’s Disease Neuroimaging Initiative, Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. Alzheimers Dement. 10, S344–S353 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Gu Y., et al., Brain amyloid deposition and longitudinal cognitive decline in nondemented older subjects: Results from a multi-ethnic population. PLoS One 10, e0123743 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Cummings B. J., Pike C. J., Shankle R., Cotman C. W., β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer’s disease. Neurobiol. Aging 17, 921–933 (1996). [DOI] [PubMed] [Google Scholar]
- 15.Näslund J., et al., Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283, 1571–1577 (2000). [DOI] [PubMed] [Google Scholar]
- 16.Villemagne V. L., et al., Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer’s disease. Neuropsychologia 46, 1688–1697 (2008). [DOI] [PubMed] [Google Scholar]
- 17.C. R. Jack, Jr, et al., Alzheimer’s Disease Neuroimaging Initiative, Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: Implications for sequence of pathological events in Alzheimer’s disease. Brain 132, 1355–1365 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Goldsbury C., Frey P., Olivieri V., Aebi U., Müller S. A., Multiple assembly pathways underlie amyloid-β fibril polymorphisms. J. Mol. Biol. 352, 282–298 (2005). [DOI] [PubMed] [Google Scholar]
- 19.Petkova A. T., et al., Self-propagating, molecular-level polymorphism in Alzheimer’s β-amyloid fibrils. Science 307, 262–265 (2005). [DOI] [PubMed] [Google Scholar]
- 20.Tycko R., Amyloid polymorphism: Structural basis and neurobiological relevance. Neuron 86, 632–645 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Lu J. X., et al., Molecular structure of β-amyloid fibrils in Alzheimer’s disease brain tissue. Cell 154, 1257–1268 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Qiang W., Yau W. M., Lu J. X., Collinge J., Tycko R., Structural variation in amyloid-β fibrils from Alzheimer’s disease clinical subtypes. Nature 541, 217–221 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Kollmer M., et al., Cryo-EM structure and polymorphism of Aβ amyloid fibrils purified from Alzheimer’s brain tissue. Nat. Commun. 10, 1–8 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Ghosh U., Thurber K. R., Yau W. M., Tycko R., Molecular structure of a prevalent amyloid-β fibril polymorph from Alzheimer’s disease brain tissue. Proc. Natl. Acad. Sci. U.S.A. 118, e2023089118 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Xiao Y., et al., Aβ(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer’s disease. Nat. Struct. Mol. Biol. 22, 499–505 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Wälti M. A., et al., Atomic-resolution structure of a disease-relevant Aβ(1-42) amyloid fibril. Proc. Natl. Acad. Sci. U.S.A. 113, E4976–E4984 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Gremer L., et al., Fibril structure of amyloid-β(1-42) by cryo-electron microscopy. Science 358, 116–119 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Wang H. S., et al., Polymorphic Aβ42 fibrils adopt similar secondary structure but differ in cross-strand side chain stacking interactions within the same β-sheet. Sci. Rep. 10, 1–9 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Colvin M. T., et al., Atomic resolution structure of monomorphic Aβ(42) amyloid fibrils. J. Am. Chem. Soc. 138, 9663–9674 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Collinge J., Mammalian prions and their wider relevance in neurodegenerative diseases. Nature 539, 217–226 (2016). [DOI] [PubMed] [Google Scholar]
- 31.Caughey B., Raymond G. J., Bessen R. A., Strain-dependent differences in β-sheet conformations of abnormal prion protein. J. Biol. Chem. 273, 32230–32235 (1998). [DOI] [PubMed] [Google Scholar]
- 32.Safar J., et al., Eight prion strains have PrP(Sc) molecules with different conformations. Nat. Med. 4, 1157–1165 (1998). [DOI] [PubMed] [Google Scholar]
- 33.Sanders D. W., et al., Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271–1288 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Falcon B., et al., Structures of filaments from Pick’s disease reveal a novel tau protein fold. Nature 561, 137–140 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Falcon B., et al., Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 568, 420–423 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Fitzpatrick A. W. P., et al., Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature 547, 185–190 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Zhang W., et al., Novel tau filament fold in corticobasal degeneration. Nature 580, 283–287 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Tuttle M. D., et al., Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein. Nat. Struct. Mol. Biol. 23, 409–415 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Li B., et al., Cryo-EM of full-length α-synuclein reveals fibril polymorphs with a common structural kernel. Nat. Commun. 9, 1–10 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Schweighauser M., et al., Structures of α-synuclein filaments from multiple system atrophy. Nature 585, 464–469 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Guo J. L., et al., Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 154, 103–117 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Bousset L., et al., Structural and functional characterization of two α-synuclein strains. Nat. Commun. 4, 1–13 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Woerman A. L., et al., Familial Parkinson’s point mutation abolishes multiple system atrophy prion replication. Proc. Natl. Acad. Sci. U.S.A. 115, 409–414 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Meyer-Luehmann M., et al., Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313, 1781–1784 (2006). [DOI] [PubMed] [Google Scholar]
- 45.Watts J. C., et al., Serial propagation of distinct strains of Aβ prions from Alzheimer’s disease patients. Proc. Natl. Acad. Sci. U.S.A. 111, 10323–10328 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Stöhr J., et al., Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice. Proc. Natl. Acad. Sci. U.S.A. 111, 10329–10334 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Cohen M., et al., Distinct strains of Aβ prions implicated in rapidly progressive Alzheimer disease. Prion 9, S76–S77 (2015). [Google Scholar]
- 48.Rasmussen J., et al., Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 114, 13018–13023 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Condello C., et al., Structural heterogeneity and intersubject variability of Aβ in familial and sporadic Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 115, E782–E791 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Murray D. T., et al., Structure of FUS protein fibrils and its relevance to self-assembly and phase separation of low-complexity domains. Cell 171, 615–627.e16 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Elkins M. R., et al., Structural polymorphism of Alzheimer’s β-amyloid fibrils as controlled by an E22 switch: A solid state NMR study. J. Am. Chem. Soc. 138, 9840–9852 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Paravastu A. K., Qahwash I., Leapman R. D., Meredith S. C., Tycko R., Seeded growth of β-amyloid fibrils from Alzheimer’s brain-derived fibrils produces a distinct fibril structure. Proc. Natl. Acad. Sci. U.S.A. 106, 7443–7448 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Ghosh U., Yau W. M., Tycko R., Coexisting order and disorder within a common 40-residue amyloid-β fibril structure in Alzheimer’s disease brain tissue. Chem. Commun. (Camb.) 54, 5070–5073 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Kloepper K. D., Woods W. S., Winter K. A., George J. M., Rienstra C. M., Preparation of α-synuclein fibrils for solid-state NMR: Expression, purification, and incubation of wild-type and mutant forms. Protein Expr. Purif. 48, 112–117 (2006). [DOI] [PubMed] [Google Scholar]
- 55.Luca S., Yau W. M., Leapman R., Tycko R., Peptide conformation and supramolecular organization in amylin fibrils: Constraints from solid-state NMR. Biochemistry 46, 13505–13522 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Bennett D. A., et al., Religious orders study and Rush memory and aging project. J. Alzheimers Dis. 64, S161–S189 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Qiang W., Yau W. M., Tycko R., Structural evolution of Iowa mutant β-amyloid fibrils from polymorphic to homogeneous states under repeated seeded growth. J. Am. Chem. Soc. 133, 4018–4029 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Tycko R., Computer programs for RMSD and principal component analyses of 2D solid state NMR spectra. Mendeley Data. https://data.mendeley.com/datasets/3zzc2dhx26/1. Deposited 1 June 2021.
- 59.Tycko R., 2D solid state NMR spectra of brain-seeded amyloid-beta fibrils. Mendeley Data. https://data.mendeley.com/datasets/dj34fwjhkt/1. Deposited 25 May 2021.
- 60.Tycko R., Solid state NMR spectra of brain-seeded Abeta40 and Abeta42 fibrils. Mendeley Data. https://data.mendeley.com/datasets/tbp45pm92x/1. Deposited 4 August 2016.
- 61.Wold S., Esbensen K., Geladi P., Principal component analysis. Chemom. Intell. Lab. Syst. 2, 37–52 (1987). [Google Scholar]
- 62.Henry E. R., Hofrichter J., Singular value decomposition: Application to analysis of experimental data. Methods Enzymol. 210, 129–192 (1992). [Google Scholar]
- 63.Yau W. M., Tycko R., Depletion of amyloid-β peptides from solution by sequestration within fibril-seeded hydrogels. Protein Sci. 27, 1218–1230 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Aisen P. S., et al., On the path to 2025: Understanding the Alzheimer’s disease continuum. Alzheimers Res. Ther. 9, 1–10 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Barulli D., Stern Y., Efficiency, capacity, compensation, maintenance, plasticity: Emerging concepts in cognitive reserve. Trends Cogn. Sci. 17, 502–509 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Busche M. A., Hyman B. T., Synergy between amyloid-β and tau in Alzheimer’s disease. Nat. Neurosci. 23, 1183–1193 (2020). [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The 2D solid-state NMR spectra data that support the findings of this study have been deposited in Mendeley Data (https://data.mendeley.com/datasets/dj34fwjhkt/1). Computer programs written specifically for the analyses in Figs. 4 and 5 have been deposited in Mendeley Data (https://data.mendeley.com/datasets/3zzc2dhx26/1). Previously published data were also used for this work (https://data.mendeley.com/datasets/tbp45pm92x/1).